Biomark Diagnostics
  • Home
  • About BioMark
    • About Us
    • BioMark Technology
    • Publications & Scientific Posters
    • Awards and Achievements
    • Strategic Collaborations
    • Cancer Education Videos
  • Oncology Platform
    • Biomark SSAT1 Assay
    • BioMark Metabolic Panel
  • Investor Relations
    • Stock Quote
    • News Releases
    • Investment Highlights
    • Corporate Presentations and Communication
  • Bio-Stream Diagnostics
    • Bio-Stream Spectral Test
  • Recent Posts
  • Info & Contact

News Releases

« Back to News

BioMark Diagnostics to Conduct Validation Studies for its Patented Assays in Patients with Lung Cancer

Dr. James Bond of Surrey Memorial Hospital to act as Principal Investigator

September 10, 2015

BioMark Diagnostics to Conduct Validation Studies (PDF)

 

———————————————

< BioMark Diagnostics Receives Clearance from Health Canada to Commence Clinical Trial with Patented Non-Invasive, Urine-Based Assay to Measure Response to Treatment for Lung Cancer BioMark Diagnostics to Conduct Validation Studies for its Patented Assays in Patients with Lung Cancer

Dr. James Bond of Surrey Memorial Hospital to act as Principal Investigator

>

ARCHIVES

  • 2020 News Release
  • 2019 News Release
  • 2018 News Release
  • 2017 News Release
  • 2016 News Release
  • 2015 News Release
  • 2014 News Release
Further information about BioMark is available under its profile on:
SEDAR website:
http://www.sedar.com
CSE website:
http://thecse.com

Sitemap

  • Home
  • About BioMark
    • About Us
    • BioMark Technology
    • Publications & Scientific Posters
    • Awards and Achievements
    • Strategic Collaborations
    • Cancer Education Videos
  • Oncology Platform
    • Biomark SSAT1 Assay
    • BioMark Metabolic Panel
  • Investor Relations
    • Stock Quote
    • News Releases
    • Investment Highlights
    • Corporate Presentations and Communication
  • Bio-Stream Diagnostics
    • Bio-Stream Spectral Test
  • Recent Posts
  • Info & Contact

Latest Posts

  • Missing cancer cases a worrying pandemic trend
  • World Cancer Day: A leading international awareness day
  • Doctors fear an impending wave of cancer patients after COVID-19 delays
  • Richmond company looking for ‘holy grail’ in COVID-19 testing
  • Dr. Horacio Bach – receives major grant from CIHR for COVID-19 antibody development

Site Policies

  • Terms and Conditions
  • Website and Privacy Policy

Contact Us

INVESTOR CORPORATE INQUIRES

RASHID A. BUX
  • CEO
  • 604.370.0779
  • info@biomarkdiagnostics.com

Copyright © 2019 BioMark Diagnostics Inc. All rights reserved.

Biomark Diagnostics

BioMark's mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.